Physician profile
Lance L Stein
NPI 1568558062
$941,293.85
in general payments reported to CMS, 2019-2025
36 companies · $315K in 2025
The $315K reported for 2025 was more than what 99% of Transplant Hepatology providers received nationally (typical 2025 total: $508).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $125K · 2020: $43K · 2021: $112K · 2022: $81K · 2023: $74K · 2024: $192K · 2025: $315K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $433K · Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program: $70K · Consulting Fee: $40K · Travel and Lodging: $22K · Food and Beverage: $14K · Honoraria: $1,080.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $433,432.00 |
| Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program | $70,470.00 |
| Consulting Fee | $39,568.50 |
| Travel and Lodging | $21,547.64 |
| Food and Beverage | $14,158.23 |
| Honoraria | $1,080.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Intercept Pharmaceuticals, INC. | $263,337.29 | 2019-2025 | Ocaliva |
| Abbvie INC. | $182,176.47 | 2019-2025 | Mavyret |
| Madrigal Pharmaceuticals | $179,542.01 | 2024-2025 | Rezdiffra, Resmetirom |
| Gilead Sciences, INC. | $129,019.80 | 2019-2025 | Livdelzi, Epclusa |
| Ipsen Biopharmaceuticals, INC | $113,848.07 | 2024-2025 | Iqirvo, Bylvay |
| Mallinckrodt Hospital Products INC. | $62,767.29 | 2022-2025 | Terlivaz, Acthar |
| Glaxosmithkline, LLC. | $2,600.00 | 2023 | |
| Bausch Health US, LLC | $2,187.50 | 2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $1,494.71 | 2019-2025 | Xifaxan, Plenvu |
| Fujifilm Healthcare Americas Corporation | $1,194.33 | 2020-2025 | Utaswako Afp-L3 |
| Boston Scientific Corporation | $579.19 | 2022-2024 | Therasphere Y90 Glass Microspheres 10 Gbq |
| Zoll Medical Corporation | $500.00 | 2023 | |
| Medtronic, INC. | $465.00 | 2021 | |
| Novo Nordisk INC | $254.01 | 2025 | Wegovy |
| Alnylam Pharmaceuticals INC. | $187.50 | 2019 |
Show all 36 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alexion Pharmaceuticals, INC. | $152.32 | 2020-2025 | Ultomiris |
| Orphalan INC | $138.70 | 2024-2025 | Cuvrior |
| Astellas Pharma US INC | $117.35 | 2022-2025 | Cresemba |
| Amgen INC. | $83.09 | 2025 | Uplizna |
| Intra-Sana Laboratories | $82.11 | 2022 | |
| Astrazeneca Pharmaceuticals Lp | $62.88 | 2020-2025 | |
| Trisalus Life Sciences, INC. | $51.63 | 2025 | Trinav Infusion System |
| Novo Nordisk As | $50.00 | 2024 | |
| Invivyd INC | $47.50 | 2025 | Pemgarda |
| Sirtex Medical INC | $46.15 | 2025 | Sir-Spheres Microspheres |
| Ethicon US, LLC | $42.58 | 2025 | Surgicel Nu-Knit, Vistaseal |
| Vifor Pharma, INC. | $38.95 | 2019 | |
| Pfizer INC. | $37.08 | 2023 | |
| Ucb, INC. | $36.96 | 2019 | |
| Mirum Pharmaceuticals, INC. | $24.71 | 2025 | Livmarli |
| Ani Pharmaceuticals, INC. | $24.52 | 2025 | Purified Cortrophin Gel |
| Azurity Pharmaceuticals, INC. | $23.85 | 2025 | |
| Kadmon Pharmaceuticals LLC | $21.35 | 2020 | |
| Bayer Healthcare Pharmaceuticals INC. | $20.31 | 2019 | |
| Fujifilm Wako Diagnostics U.S.A. Corporation | $20.20 | 2019 | |
| Calliditas Therapeutics US INC. | $18.44 | 2023 | Tarpeyo |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Lance Stein listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.